Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from CTI BioPharma

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Mar 1, 2022

CTI BioPharma's Bone Marrow Cancer Drug Scores FDA Approval

CTI BioPharma's Bone Marrow Cancer Drug Scores FDA Approval

The FDA approved CTI BioPharma Corp's (NASDAQ:CTIC) Vonjo (pacritinib) for treating adult patients with myelofibrosis, a type of bone marrow cancer with low blood platelets count. Pacritinib is a JAK inhibitor and will compete with Incyte Corporation's (NASDAQ:INCY) Jakafi and Bristol Myers Squibb's Co (NYSE:BMY) Inrebic, which were approved in 2011 and 2019, respectively for myelofibrosis. CTI…

Benzinga · Mar 1, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

1

Coverage From

Benzinga

Organisations

Bristol Myers Squibb

Incyte Corporation

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play